In the coming quarter, we expect to introduce a new revenue stream through data-licensing, which will have a significant positive impact on our revenue, margins and enterprise value. Regarding Corellia, our wholly-owned drug development subsidiary, we remain highly enthusiastic about the targets and compounds we have developed using our proprietary data. We are actively engaged in discussions to raise capital for the company. As with all of our cost centers, we are mindful of the impact on our bottom-line r ...